A report of 9 cases of living donor kidney transplantation from ABO-incompatible relatives
10.3760/cma.j.cn421203-20200213-00035
- VernacularTitle:ABO血型不相容亲属活体肾移植九例报告
- Author:
Hua CHEN
1
;
Lizhi LI
;
Shaohua SHI
;
Zhenghua WU
;
Jun YANG
;
Tingting LIU
;
Jiali WANG
;
Xunan TONG
;
Bodan ZHANG
;
Zhenxing WANG
Author Information
1. 山西白求恩医院器官移植中心 山西省第二人民医院，太原 030010
- From:
Chinese Journal of Organ Transplantation
2020;41(5):271-274
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the clinical experiences of 9 ABO-incompatible kidney transplantation at our center and explore its clinical application value.Methods:Methods From April 2016 to December 2019, there were 9 living kidney transplants of ABO incompatible relatives, including type A to type B (n=3), type B to type O (n=3), type B to type A (n=1) and type AB to type B (n=2). Immunosuppressant plus single membrane plasmapheresis (PE) and/or double filtration plasmapheresis (DFPP) and rituximab were employed for pretreating recipients. Adverse reactions of recipients were observed during and after pretreatment. Blood group antibody titer, complications and other related parameters were recorded before and after transplantation before and after monitoring pretreatment.Results:After pretreatment, IgM, IgG and total titer of blood group antibodies were ≤1: 4 on the day of transplantation and the titer of non-blood group antibodies rebounded within 2 weeks (≤1: 8). During preconditioning, 2 patients experienced oral numbness and involuntary dithering during plasmapheresis and there was 1 case of infusion reaction after rituximab dosing. The early recovery of renal function was all excellent. Renal biopsy was performed in 4 patients with slow elevation of serum creatinine and 1 case developed acute antibody-mediated rejection. The survival rate of all recipients at the last follow-up was 100%.Conclusions:Live kidney transplantation of ABO-incompatible relatives is both safe and feasible so that it may help alleviate some shortage of donor kidney.
